Reflexivity and truth: A genealogy of the place of the university
In: The European legacy: the official journal of the International Society for the Study of European Ideas (ISSEI), Band 1, Heft 3, S. 885-890
ISSN: 1470-1316
11 Ergebnisse
Sortierung:
In: The European legacy: the official journal of the International Society for the Study of European Ideas (ISSEI), Band 1, Heft 3, S. 885-890
ISSN: 1470-1316
In: International educational studies 4
On July 16th, 2020, the Court of Justice of the European Union issued a landmark decision in the case of Data Protection Commissioner v. Facebook Ireland Ltd, Maximillian Schrems (Schrems II) concerning the legality of Facebook's transfers of personal data from the EU to the US. The decision has potentially significant effects on the ability of researchers to legitimately transfer personal data for health research purposes from countries inside the EU, to third countries outside the EU. This article aims: i) to outline the consequences of the Schrems II decision for the legitimate sharing of personal data for health research between the EU and third countries, particularly in the context of the COVID-19 pandemic; and, in light of this elaboration, ii) to consider the avenues that might be pursued to remedy challenges posed by the decision and to facilitate international data exchange for health research moving forward.
BASE
On 16 July 2020, the Court of Justice of the European Union issued their decision in the Schrems II case concerning Facebook's transfers of personal data from the EU to the US. The decision may have significant effects on the legitimate transfer of personal data for health research purposes from the EU. This article aims: (i) to outline the consequences of the Schrems II decision for the sharing of personal data for health research between the EU and third countries, particularly in the context of the COVID-19 pandemic; and, (ii) to consider certain options available to address the consequences of the decision and to facilitate international data exchange for health research moving forward.
BASE
On 16 July 2020, the Court of Justice of the European Union issued their decision in the Schrems II case concerning Facebook's transfers of personal data from the EU to the US. The decision may have significant effects on the legitimate transfer of personal data for health research purposes from the EU. This article aims: (i) to outline the consequences of the Schrems II decision for the sharing of personal data for health research between the EU and third countries, particularly in the context of the COVID-19 pandemic; and, (ii) to consider certain options available to address the consequences of the decision and to facilitate international data exchange for health research moving forward.
BASE
On July 16th, 2020, the Court of Justice of the European Union issued a landmark decision in the case of Data Protection Commissioner v. Facebook Ireland Ltd, Maximillian Schrems (Schrems II) concerning the legality of Facebook's transfers of personal data from the EU to the US. The decision has potentially significant effects on the ability of researchers to legitimately transfer personal data for health research purposes from countries inside the EU, to third countries outside the EU.[1] This article aims: i) to outline the consequences of the Schrems II decision for the legitimate sharing of personal data for health research between the EU and third countries, particularly in the context of the COVID-19 pandemic; and, in light of this elaboration, ii) to consider the avenues that might be pursued to remedy challenges posed by the decision and to facilitate international data exchange for health research moving forward.
BASE
SSRN
Working paper
In: http://hdl.handle.net/2027/osu.32435071103592
Thomas Harrison was tried in 1638 in the Court of King's bench. ; Hampden was tried, 1637-38, in the Court of exchequer chamber, on a writ of scire facias brought in the Court of exchequer, requiring him to show cause why he should not be charged with 20 shillings assessed upon him. ; "The Collection of state-tryals in four volumes in folio, being a work so very useful and necessary, to make it more compleat, it was thought fitting . to add to it the remarkable tryal of Mr. Hambden . For that reason therefore we caused it to be printed of the same size, and on the same paper."--Pref. ; Another issue, with same imprint and pagination, has title: The tryal of John Hampden . ; Mode of access: Internet.
BASE
[2], 48 p. ; Reproduction of original in Huntington Library. ; Sir Robert Berkeley was charged with treason, the others were impeached. The charges included that of delivering opinions favorable to the right of the crown to collect ship-money.
BASE
Background—misinformation and mistrust often undermines community vaccine uptake, yet information in rural communities, especially of developing countries, is scarce. This study aimed to identify major challenges associated with coronavirus disease 2019 (COVID-19) vaccine clinical trials among healthcare workers and staff in Uganda. Methods—a rapid exploratory survey was conducted over 5 weeks among 260 respondents (66% male) from healthcare centers across the country using an online questionnaire. Twenty-seven questions assessed knowledge, confidence, and trust scores on COVID-19 vaccine clinical trials from participants in 46 districts in Uganda. Results—we found low levels of knowledge (i.e., confusing COVID-19 with Ebola) with males being more informed than females (OR = 1.5, 95% CI: 0.7–3.0), and mistrust associated with policy decisions to promote herbal treatments in Uganda and the rushed international clinical trials, highlighting challenges for the upcoming Oxford–AstraZeneca vaccinations. Knowledge, confidence and trust scores were higher among the least educated (certificate vs. bachelor degree holders). We also found a high level of skepticism and possible community resistance to DNA recombinant vaccines, such as the Oxford–AstraZeneca vaccine. Preference for herbal treatments (38/260; 14.6%, 95% CI: 10.7–19.3) currently being promoted by the Ugandan government raises major policy concerns. High fear and mistrust for COVID-19 vaccine clinical trials was more common among wealthier participants and more affluent regions of the country. Conclusion—our study found that knowledge, confidence, and trust in COVID-19 vaccines was low among healthcare workers in Uganda, especially those with higher wealth and educational status. There is a need to increase transparency and inclusive participation to address these issues before new trials of COVID-19 vaccines are initiated.
BASE